ArticleDiscover oncology2025
Analysis of ABCC3 in glioma progression: implications for prognosis, immunotherapy, and drug resistance.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Overcoming barriers: mechanisms and strategies of nanoparticles in overcoming the blood-brain barrier and drug resistance in glioblastomas.Journal of the Egyptian National Cancer Institute · 2026Review
- Research progress on glioma drug resistance: mechanism analysis and therapeutic strategies.Frontiers in pharmacology · 2026Review
- Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
As a primary brain cancer, glioma presents significant challenges in treatment and prognosis. Identifying reliable biomarkers is crucial for improving patient outcomes. This study focuses on the ABCC3 gene, exploring its function as a standalone predictive indictor and its correlation with immune infiltration and resistance to chemotherapy in glioma. A multi-faceted approach was adopted for this analysis. We scrutinized the RNA expression patterns of the ABCC3 gene across a spectrum of cancer types, with a concentrated focus on glioma. Our methodological arsenal included bioinformatics analysis, immunohistochemistry (ICH), western blot (WB), and cell counting Kit-8 (CCK8) assays. These techniques were instrumental in gauging the prognostic impact of ABCC3 and elucidating its associations with immune cell infiltration and chemotherapy resistance. The investigation revealed a significant elevated levels of ABCC3 in high grade glioma (HGG) tissues compared to lower grade glioma (LGG) tissues. Notably, upregulation of ABCC3 were associated with a shorter overall survival in patients with glioma. Furthermore, ABCC3 emerged as an independent factor in prognostication, with predictive capability for 1-, 3-, and 5-year survival rates. As far as immune response is concerned, ABCC3's expression correlates positively with the expression of several immune cells and checkpoint genes. The study also uncovered the role of ABCC3 in drug resistance, particularly regarding temozolomide (TMZ), a primary therapeutic agent in glioma treatment. The study reveals ABCC3 as a significant biomarker in glioma, associated with lower survival, enhanced immune infiltration, and increased resistance to chemotherapy. These findings emphasize its promise as a novel target for glioma therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.